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Estrogen receptorAbstract Purpose: To observe the effect of cynomorium total flavone on the depression model of
perimenopausal rat and to analyze the action characteristics of cynomorium total flavone on
depression of rat with perimenopausal syndrome.
Method: Duplicate the model of rat with perimenopausal depression based on the combined
method of incomplete castration and chronic stimulation, and keep drug administration for 35d.
And then measure related behavior indicators and the change of biochemical index level in serum
and brains; measure the estrogen/androgen receptor (ER/AR) in related tissues and the ERmRNA
expression in hypothalamus.
Result: It can be seen that cynomorium total flavone can significantly improve the behavior indi-
cators of rat with perimenopausal depression; obviously or significantly change the level of related
biomedical indexes in serum and brains of perimenopausal depressed rat; obviously or significantly
increase the expression of ER/AR in related tissues of perimenopausal depressed rat; obviously or
significantly increase the ERmRNA expression in hypothalamus.
Conclusion: Cynomorium total flavone can adjust hypothalamic-pituitary-gonadal axis by
increasing E2, and make related biomedical indexes and hormone receptors tend to be normal,
so as to relieve perimenopausal syndrome and perimenopausal syndrome with depression.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
With the increase in age and decline of ovarian function, estro-
gen secretion is gradually decreased, which leads to the dyse-quilibrium of HPO and hypothalamic-hypophyscal-ovarian
axis (HPOA) and impacts autonomic center function and the
functions of various organs controlled by autonomic center,
thus causing a series of symptoms called perimenopause syn-
drome (PMS) or climacteric syndrome (CS). Epidemiological
investigation was performed for women’s perimenopausal syn-
drome in Shanghai, showing that those with depression ten-
dency account for 77.29% of total respondents, while those
with depression symptoms account for 8.36%, and both
belong to common symptoms of patients with PMS. Studies
believe that the incidence of risk in general as early as 40 years
old will begin to appear (Judy, 2011). In addition, studies have
140 M. Miao et al.indicated that PMS symptoms can decrease the quality of life
of PMS patients and increase the risk of the disease. So seeking
another safe and effective therapy is in urgent need. At the ini-
tial phase of this experiment, we have done pharmacodynamic
study on total flavonoids applied in mouse model of peri-
menopause. The study proves that total flavonoids from
Cynomorium songaricum can improve related indicators of
mouse model of perimenopause; but it lacks the discussion
about the action and mechanism of total flavonoids from
Cynomorium songaricum on animal models of peri-
menopausal depression. Therefore, this article will mainly
study the action and mechanism of Cynomorium songaricum
on the mouse model of perimenopausal depression.2. Materials and methods
2.1. Experimental animal
SD rat; female; SPF level body weight: 250–270 g; Supplier:
Shandong Lukang Pharmaceutical Co., Ltd.; Certification
number of the animal: 0021925; Certification number of the
laboratory: SYXK (Henan Province) 2010-001.
2.2. Experimental drug
Cynomorium total flavone prepared in Office of Chemistry,
Henan University of Traditional Chinese Medicine, purity:
50.87%, batch number ZL20140716. Gengnianan capsules:
produced by Shanxi Tianxing Pharmaceutical Co., Ltd. Batch
number: 140112. Soybean Isoflavones Vitamin E Soft Cap-
sules: produced by Weihai Purple Light Biotechnology Devel-
opment Co., Ltd. Batch number: 14040301.
2.3. Experiment method
From 100 female wistar rats with weight ranging from 250 to
270 g, randomly selecting out 12 as blank group for sham-
operation, and the menopausal models of the remaining rats
are established. After weighing, injecting 10% chloral hydrate
(0.3 ml/100 g) for anesthesia before fixing their abdominal
regions, and then completely extirpating the left ovary and
extirpating 80% of right ovary before suturing well the muscle
and skin. After operation, carefully feeding them and injecting
penicillin 200,000 u/kg (0.1 ml per rat) one a day for consecu-
tively 3 days. From the 5th after operation, vaginal smear
examination is applied on every single rat once a day for con-
secutively 5d. Those showing emotional reactions are not used,
and finally 72 completely castrated rats are randomly divided
into 6 groups including Gengnianan capsule group (fed with
Gengnianan capsule suspension of 0.45 mg/kg, which equals
10 times of the clinical dosage), Soybean Isoflavones Vitamin
E Soft Capsules group (fed with Soybean Isoflavones suspen-
sion of 0.167 mg/kg, which equals 10 times of the clinical
dosage), big dosage cynomorium total flavone group (fed with
0.2 g/kg cynomorium total flavone, which equals 20 times of
the clinical dosage), medium dosage cynomorium total flavone
group (fed with 0.1 g/kg cynomorium total flavone, which
equals 10 times of the clinical dosage), and small dosage
cynomorium total flavone group (fed with 0.05 g/kg cynomo-rium total flavone, which equals 5 times of the clinical
dosage). In addition, both blank group and model group are
fed with 0.5% CMC solution of the same volume. Drug
administration is given by 1 ml/100 g once a day for consecu-
tively 35 days.
After keeping drug administration for 5 days, rats in the
blank group are kept by 6 rats per cage without any simula-
tions; while for the 6 model groups, rats are kept by 1 rat per
cage, which is randomly applied with one from 6 different
simulations including damp bedding (bedding: g, water: ml),
ice water swimming (4 C, 5 min), heat stress (45 C, 5 min),
all-day illumination (24 h), water deprivation (24 h), food
deprivation (24 h), wherein it is worth noting that in the 18
consecutive days of medication period, a random simulation
is given per day, and no same simulation should be arranged
in 2 consecutive days. From the 1st day after simulation,
open field is tested to observe stand-up times and horizontal
move distance of all groups of rats. From the second day
after simulation, forced swimming test is given to measure
the immobility time within 4 days. From the 3rd or 4th day
from simulation, sugar consumption experiment, prior to
which 12 h of water deprivation is conducted, is given to
measure 1% sugar water intake within 24 h of food
deprivation.
At 2 h after final gavage (food deprivation for 15 h), draw
the blood from the eyeball of the rat and measure the content
of estradiol (E2 and testosterone (T) according to the instruc-
tion of test kits. Extricate brain homogenate and measure the
content of methylepinephrine (NE), dopamine (DA),
5-hydroxytryptamine (5-HT) according to related instruction
of test kits; extirpate uterus and remaining 20% ovarian tissue,
extricate hypothalamus and hypophysis, and then fix the left
side of the hypothalamus, hypophysis, uterus, and ovary in
10% formaldehyde solution before being processed into paraf-
fin embedding sections to measure the expression of estrogen
receptor (ER) in hypothalamus, hypophysis, uterus, and
ovary, as well as the expression of AR in hypothalamus and
hypophysis using the immunohistochemical method. On the
other hand, store the right side of the hypothalamus in
80 C refrigerator and measure the expression of ERmRNA
using the RT-PCR method.
2.4. Statistical processing method
Data are statistically processed and analyzed using SPSS17.0
medical statistical package, and measurement data are
expressed by mean value ± standard deviation (x s). One-
way analysis of variance is performed for each group, wherein
those of equal variance are tested by the LSD method, while
those of heterogeneous variances are tested by the Games-
Howell method.3. Results
3.1. Effect on the behaviors of perimenopausal rats with
depression
Effect on open-field test of perimenopausal rats with depres-
sion, and the results are shown in Table 1.
Table 1 Effect of synomorium total flavone on open-field test of perimenopausal rats with depression ( X s).
Group no. Movement distance (cm) Stand-up times (time)
Blank group 1577.42 ± 94.33** 24.00 ± 1.91**
Model group 952.83 ± 89.56 13.36 ± 1.50
Soybean Isoflavones Vitamin E Soft Capsules group 1313.424 ± 90.69** 21.55 ± 2.02**
Gengnianan capsule group 1337.69 ± 94.63** 21.73 ± 1.42**
Big dosage cynomorium total flavone group 1297.31 ± 99.49** 20.91 ± 1.76**
Medium dosage cynomorium total flavone group 1225.33 ± 100.24** 18.60 ± 1.91**
Small dosage cynomorium total flavone group 1179.95 ± 86.04** 17.73 ± 1.74**
Note: compared with model group.
*P< 0.05.
** P< 0.01.
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rats in the blank group, rats in the model group show a signif-
icant decrease of movement distance and stand-up times
(P< 0.01), indicating that the perimenopausal depressed rats
suffer decreased curiosity of fresh environment. Compared
with rats in the model group, it can be seen that the big/med-
ium/small dosage of cynomorium total flavone, Gengnianan
capsule, and Soybean Isoflavones Vitamin E Soft Capsule
can all significantly increase the movement distance and
stand-up times of perimenopausal rats with depression
(P< 0.01).
The effect of sugar water intake and immobility time in the
forced swimming test of perimenopausal rats with depression
is shown in Table 2.
According to Table 2, it can be seen that compared with
rats in blank group, rats in the model group have an signifi-
cantly extended immobility time (P< 0.01) in the forced
swimming test and a significantly decreased sugar water intake
(P< 0.01), indicating that the perimenopausal rats with
depression have a higher degree of desperation upon adverse
environment and a declined reaction upon reward. Compared
with rats in the model group, Soybean Isoflavones Vitamin E
Soft Capsule, Gengnianan capsule, and big/medium dosage
of cynomorium total flavone can significantly decrease the
immobility time (P< 0.01) in the forced swimming test and
significantly increase the sugar water intake (P< 0.01); how-
ever, small dosage of cynomorium total flavone can signifi-
cantly increase the sugar water intake (P< 0.01) of
perimenopausal rats with depression while merely leading to
decreasing tendency of the immobility time in the forced swim-
ming test.Table 2 Effect of cynomorium total flavones on sugar water intake




Soybean Isoflavones Vitamin E Soft Capsules group
Gengnianan capsule group
Big dosage cynomorium total flavone group
Medium dosage cynomorium total flavone group
Small dosage cynomorium
total flavone group
Note: compared with the model group.
*P< 0.05.
** P< 0.01.3.2. Effect on biomedical indexes in the serum of perimenopausal
rats with depression
Contents of E2 and T in serum of rats in all groups are shown
in Table 3.
According to Table 3, it can be seen that compared to rats
in the blank group, those in the model group suffer a signifi-
cantly decreased level of E2 and T in the serum, indicating that
incomplete removal of ovary can lead to sex hormone distur-
bances of perimenopausal rats, and the model replications of
perimenopausal rats are successful. Compared to rats in the
model group, it can be seen that big dosage of cynomorium
total flavone, Gengnianan capsule, and Soybean Isoflavones
Vitamin E Soft Capsule can all significantly increase the E2
level of perimenopausal rats with depression (P< 0.01), while
small/medium dosage of cynomorium total flavone can merely
lead to the increasing tendency of E2 level of perimenopausal
rats with depression; on the other hand, medium dosage of
cynomorium total flavone and Soybean Isoflavones Vitamin
E Soft Capsule can significantly increase the T level of peri-
menopausal rats with depression (P< 0.05), while small
dosage of cynomorium total flavone can barely lead to increas-
ing tendency of L level.
3.3. Effect on biomedical indexes in brain homogenate of
perimenopausal rats with depression
Effect on the level of 5-HT and DA in brain homogenate of
perimenopausal rats with depression, and the results are shown
in Table 4.and immobility time in forced swimming test of perimenopausal
Immobility time (s) Sugar water intake (ml)
58.94 ± 7.29** 104.08 ± 6.82**
113.73 ± 8.16 61.36 ± 6.23
96.27 ± 9.09** 90.27 ± 6.60**
89.64 ± 7.40** 86.55 ± 7.53**
83.62 ± 9.56** 84.45 ± 8.77**
94.09 ± 8.95** 80.00 ± 5.75**
100.64 ± 9.32 76.64 ± 6.47**
Table 4 Effect of cynomorium total flavones on the level of 5-HT and DA in brain homogenate of perimenopausal rats with
depression ( X s).
Group no. 5-HT (ng/ml) DA (pg/ml)
Blank group 58.31 ± 6.45** 1191.93 ± 70.13**
Model group 37.95 ± 4.39 799.02 ± 50.49
Soybean Isoflavones Vitamin E Soft Capsules group 50.27 ± 4.65** 1042.82 ± 80.47**
Gengnianan capsule group 52.63 ± 4.85** 1082.08 ± 89.44**
Big dosage cynomorium total flavone group 48.58 ± 4.79** 998.72 ± 91.89**
Medium dosage cynomorium total flavone group 51.54 ± 2.65** 959.88 ± 128.49
Small dosage cynomorium total flavone group 44.92 ± 3.62* 891.35 ± 101.94
Note: compared with model group.
* P< 0.05.
** P< 0.01.
Table 3 Effect of synomorium total flavone on contents of E2 and T in the serum of perimenopausal rats with depression ( X s).
Group no. E2 (pmol/L) T (pg/ml)
Blank group 36.25 ± 2.54** 96.37 ± 7.68**
Model group 25.84 ± 2.62 63.31 ± 8.42
Soybean Isoflavones Vitamin E Soft Capsules group 32.84 ± 2.28** 78.13 ± 6.95*
Gengnianan capsule group 31.93 ± 1.64** 80.37 ± 7.93**
Big dosage cynomorium total flavone group 31.08 ± 1.36** 78.42 ± 9.41*
Medium dosage cynomorium total flavone group 29.96 ± 3.46 80.23 ± 8.28**
Small dosage cynomorium total flavone group 28.42 ± 1.57 74.13 ± 6.39
Note: compared with model group.
* P< 0.05.
** P< 0.01.
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rats in the blank group, rats in model groups enjoy a signifi-
cantly increased level of 5-HT and DA in brain homogenate,
indicating that the chronic stress-induced depressive model is
established successfully. In addition, as compared with rats
in the model group, big/medium dosage of cynomorium total
flavone, Gengnianan capsule, and Soybean Isoflavones Vita-
min E Soft Capsule can significantly increase the 5-HT level
in brain homogenate of rats (P< 0.01), while a small dosage
of cynomorium total flavone can significantly increase the level
of 5-HT (P< 0.05); on the other hand, Gengnianan capsule,
Soybean Isoflavones Vitamin E Soft Capsule, and big dosage
of cynomorium total flavone can all significantly increase the
DA level in brain homogenate (P< 0.01), while medium/small
dosage of cynomorium total flavone can merely lead to the
increasing tendency of DA level in the brain homogenate.Table 5 Effect of cynomorium total flavones on ER expression of pe
Group no. Hypophysis
Blank group 0.097 ± 0.010
Model group 0.048 ± 0.008
Soybean Isoflavones Vitamin E Soft Capsules group 0.084 ± 0.011
Gengnianan capsule group 0.081 ± 0.011
Big dosage cynomorium total flavone group 0.078 ± 0.009
Medium dosage cynomorium total flavone group 0.072 ± 0.011
Small dosage cynomorium total flavone group 0.067 ± 0.006
Note: compared with the model group.
*P< 0.05.
** P< 0.01.3.4. Effect on immunohistochemical indexes of perimenopausal
rats with depression
Effects on ER expression in uterus, ovary, hypophysis and
hypothalamus as well as AR expression in hypophysis and
hypothalamus. Results are shown in Tables 5 and 6 and
Figs. 1–6.
According to Table 6, it can be seen that as compared with
rats in the blank group, rats in the model group suffer a signif-
icant decrease of both ER and AR expression (P< 0.01), indi-
cating that the distributions of sex hormone receptors in
related tissues of perimenopausal depressed rats are decreased
due to incomplete removal of ovary and chronic stimulations,
and thus the biological effect of estrogen and androgen is
reduced. On the other hand, as compared with rats in the
model group, big dosage of cynomorium total flavone,rimenopausal rats with depression (mean optical density) ( X s).
Hypothalamus Uterus Ovary
** 0.130 ± 0.015** 0.153 ± 0.014** 0.101 ± 0.009**
0.042 ± 0.006 0.063 ± 0.011 0.050 ± 0.007
** 0.123 ± 0.023** 0.129 ± 0.013** 0.093 ± 0.014**
** 0.103 ± 0.018** 0.119 ± 0.017** 0.079 ± 0.010**
** 0.095 ± 0.020** 0.108 ± 0.013** 0.084 ± 0.009**
** 0.083 ± 0.015** 0.101 ± 0.010** 0.080 ± 0.011**
** 0.070 ± 0.013** 0.099 ± 0.008** 0.069 ± 0.011**
Table 6 Effect of cynomorium total flavones on AR expression of perimenopausal rats with depression (mean optical density) ( X s).
Group no. Hypophysis Hypothalamus
Blank group 0.133 ± 0.011** 0.192 ± 0.024**
Model group 0.056 ± 0.008 0.107 ± 0.019
Soybean Isoflavones Vitamin E Soft Capsules group 0.094 ± 0.012** 0.149 ± 0.021**
Gengnianan capsule group 0.118 ± 0.010** 0.156 ± 0.023**
Big dosage cynomorium total flavone group 0.117 ± 0.010** 0.146 ± 0.016**
Medium dosage cynomorium total flavone group 0.102 ± 0.011** 0.137 ± 0.024
Small dosage cynomorium total flavone group 0.089 ± 0.016** 0.120 ± 0.017
Note: compared with the model group.
*P< 0.05.
** P< 0.01.
Figure 1 AR immunohistochemistry in hypothalamus of perimenopausal rats with depression. (a) Blank group 400, (b) model group
400, (c) Soybean Isoflavones Vitamin E Soft Capsules group400, (d) Gengnianan capsule group400, (e) big dosage cynomorium total
flavone group 400, (f) medium dosage cynomorium total flavone group 400, (g) small dosage cynomorium total flavone group 400.
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Capsule can all increase the ER expression in uterus, ovary,
hypophysis and hypothalamus (P< 0.01), and significantly
increase AR expression in hypophysis and hypothalamus
(P< 0.01); while small/medium dosage of cynomorium total
flavone can significantly the ER expression in the uterus,
ovary, hypophysis and hypothalamus (P< 0.01), significantly
increase AR expression in hypophysis (P< 0.01), while merely
cause the increasing tendency of AR expression in the
hypothalamus.
3.5. Effect on ERmRNA expression
Effect of cynomorium total flavone on ERmRNA expression
in hypothalamus of perimenopausal rats with depression. See
Table 7.
According to Table 7, it can be seen that compared to rats
in the blank group, those in the model group suffer a signifi-cant decrease of ERmRNA expression in the hypothalamus,
indicating the ERmRNA expressions of perimenopausal
depressed rats are limited due to the incomplete removal of
ovary and chronic stimulations. On the other hand, compared
with rats in the model group, it can be seen that big dosage of
cynomorium total flavone, Gengnianan capsule, and Soybean
Isoflavones Vitamin E Soft Capsule can all significantly
increase ERmRNA expression in the hypothalamus
(P< 0.01), while small/medium dosage of cynomorium total
flavone can significantly improve ERmRNA expression in
hypothalamus (P< 0.05).4. Discussion
To treat CS, normally psychotherapy or sedative therapy is
given to reduce uncomfortable symptoms. However, for those
with more severe symptoms are basically given HRT, which is
Figure 2 ER Immunohistochemistry in hypothalamus of perimenopausal rats with depression. (a) Blank group 400, (b) model group
400, (c) Soybean Isoflavones Vitamin E Soft Capsules group 400, (d) Gengnianan capsule group 400, (e) big dosage cynomorium
total flavone group 400, (f) medium dosage cynomorium total flavone group 400, and (g) small dosage cynomorium total flavone
group 400.
Figure 3 ER Immunohistochemistry in ovary of perimenopausal rats with depression. (a) Blank group 400, (b) model group 400, (c)
Soybean Isoflavones Vitamin E Soft Capsules group 400, (d): Gengnianan capsule group 400, (e) big dosage cynomorium total flavone
group 400, (f) medium dosage cynomorium total flavone group 400, and (g) small dosage cynomorium total flavone group 400.
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Figure 4 ER Immunohistochemistry in uterus of perimenopausal rats with depression. (a) Blank group 400, (b) model group 400, (c)
Soybean Isoflavones Vitamin E Soft Capsules group 400, (d) Gengnianan capsule group 400, (e) big dosage cynomorium total flavone
group 400, (f) medium dosage cynomorium total flavone group 400, and (g) small dosage cynomorium total flavone group 400.
Figure 5 ER Immunohistochemistry in hypophysis of perimenopausal rats with depression. (a) Blank group 400, (b) model group
400, (c) Soybean Isoflavones Vitamin E Soft Capsules group 400, (d) Gengnianan capsule group 400, (e) big dosage cynomorium
total flavone group 400, (f) medium dosage cynomorium total flavone group 400, and (g) small dosage cynomorium total flavone
group 400.
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Figure 6 AR Immunohistochemistry in hypophysis of perimenopausal rats with depression. (a) Blank group 400, (b) model group
400, (c) Soybean Isoflavones Vitamin E Soft Capsules group 400, (d) Gengnianan capsule group 400, (e) big dosage cynomorium
total flavone group 400, (f) medium dosage cynomorium total flavone group 400, and (g) small dosage cynomorium total flavone
group 400.
Table 7 Effect of cynomorium total flavone on ERmRNA expression in hypothalamus of
perimenopausal rats with depression.
Group no. ERmRNA
Blank group 0.048 ± 0.008**
Model group 0.010 ± 0.003
Soybean Isoflavones Vitamin E Soft Capsules group 0.030 ± 0.007**
Gengnianan capsule group 0.039 ± 0.009**
Big dosage cynomorium total flavone group 0.036 ± 0.011**
Medium dosage cynomorium total flavone group 0.025 ± 0.010*
Small dosage cynomorium total flavone group 0.022 ± 0.004*
Note: compared with the model group.
* P< 0.05.
** P< 0.01.
146 M. Miao et al.superior for its quick effect, highly targeted effect, and higher
success rate. In clinical practice, it is also common to use
Oryzaol Vitamin B1 and Vitamin B6 Tablets and Compound
Methypregnone and Ethinylestradiol Capsules. However,
estrogen increases the risk of getting endometrial cancer and
breast cancer (Stevenson et al., 2011). In July 2002, the Heart,
Lung, and Blood Institute of National Institutes of Health ter-
minated early WHI’s clinical trial of using estrogen proges-
terone in healthy postmenopausal women. As of now,
hormonotherapy is still a controversial issue, therefore seeking
another safe and effective therapy is in urgent need.
Traditional Chinese medicine (TCM) recovers the ‘‘dying”
follicle and slows aging ovaries by ovarian inner adjustment,
the effectiveness of which is unrivalled by estrogen in replace-
ment therapy (Love et al., 2010). TCM treatment of meno-pause has significantly fewer side effects. In the historical
medical book Questions-Ancient Natural Integrity Theory, it
was believed that the reproductive system exhaustion and
imbalance lead to menstrual disorders, reproductive function
decline and so on. Professor Guicheng (2010) pointed out
the ‘‘Heart - Kidney - Uterine Axis” theory, noting kidneys
dominate water in the lower part, the heart dominates fire in
the upper part, and only when water from kidneys is elevated,
and the fire from the heart is lowered, can the heart and kid-
neys meet, in order to balance yin and yang. Ye Yanping
had analyzed 106 clinical cases of patients before and after
menopause, and found that the percentage of patents suffering
from liver depression is up to 79.2%. In TCM theories, kid-
neys (Zheng et al., 2011) are the root of personal health before
birth, while stomach is the root of personal health after birth.
Effect of Cynomorium total flavone on depression model of perimenopausal rat 147Liu Xiaowei believed that all evidences of diseases before and
after menopause are indicated by endogenous phlegm as the
signal, while the loss of kidney essence is the root. It was
recorded in ‘‘Compendium of Materia Medica” that:
‘‘Cynomorium songaricum is warm to kidneys, good to semi-
nal fluid, moistening body, and curing impotence.” Cynomo-
rium songaricum contains a variety of biologically active
ingredients, including flavonoids, terpenes, steroids, organic
acids, sugars and glycosides, tannins and volatile ingredients
(Meng et al., 2013) commonly used in the treatment of kidney
deficiency, seminal fluid deficiency, infertility, neurasthenia
and other symptoms. Tests have showed that the flavonoids
extracted from Cynomorium songaricum can enhance exercise
endurance, and improve the body’s antioxidant (Jin and Yin,
2012) and anti-fatigue effect, which can significantly prolong
swimming time of aged rats. The flavonoids from Cynomo-
rium songaricum can improve the SOD activity of mice, and
decrease serum MDA content, indicating its antioxidant
function.
The application of Cynomorium songaricum in menopause
treatment is based on analysis of its pathogenesis. It can speed
the animal sexual maturity, protect the kidneys, replenish
body’s androgen and stimulate the secretion of estrogen,
finally balance the hormone levels, and cure menopausal syn-
drome. According to the high content of total flavonoids in
Cynomorium songaricum and the coincidence of the former’s
pharmacological activity with the latter’s main pharmacologi-
cal effects, etc., we take the total flavonoids from Cynomorium
songaricum as the main active site, and make in-depth study
on its intervention in menopausal depression.5. Conclusions
Neither existing emasculated perimenopausal animal model
nor depression animal model can comprehensively reflect the
change of reproductive endocrine hormone and neurotrans-
mitter in perimenopausal depression, but only reflect one sin-
gle aspect of the disease. In this paper, the model of
perimenopausal depressive animal was established by a two-
step method of incomplete emasculation and chronic unpre-
dictable stress, so as to effectively simulate perimenopausal
women’s clinical symptoms such as affective disorder and
bad mood due to ovary aging. Results show that after incom-
plete removal of ovary, the estrous cycle of rat disappeared,
indicating that the perimenopausal model has been success-
fully established. The experiment results indicate that the levels
of E2 and T in the serum of model animal are significantly
decreased, which further verifies that the sexual hormone dis-
turbance of the model animal has emerged.
Through observing autonomic movement test, we can judge
whether there are emerging changes of behavioral characteris-
tics such as decline of athletic ability and social communica-
tion ability, explorative ability decline, defect of attack
ability, and decline of sexual capacity. Through the sugar
water intake test, we can measure whether the reaction inten-
sity on rewards has been reduced. Through measuring
the immobility time by forced swimming test, we can observe
the desperation degree of rats. Through the open-field test,
we can measure whether the curiosity on fresh environment
has been reduced. Ovarian failure leads to the functional disor-
der of hypothalamic-pituitary-gonadal (HOP) axis, and thuscauses the dysequilibrium of hypothalamic monoamine neuro-
transmitter (Shuo and Mingsan, 2014); while the sex hormone
withdrawal induced by menopause can lead to the reduction of
monoamine neurotransmitters such as DA and 5-HT
(Mingsan et al., 2015). 5-HT is effective in adjusting mood,
sleep, alertness, memory, appetite, sexual desire, hypothalamus
– pituitary – endocrine 5-HT and body temperature (Carsote
et al., 2013); a transient lack of 5-HT will lead to bad mood,
depression psychosis and even perimenopausal depression
symptoms. In this experiment, the contents of monoamine
neurotransmitters such as 5-HT and DA in the brain homoge-
nate of model rats are significantly reduced, which is consistent
with the symptoms of depression psychosis. Therefore, we can
conclude that the model replicating method in this paper is
successful.
The experiment results show that cynomorium total flavone
can significantly reduce the move distance and stand-up times,
significantly increase sugar water intake, and significantly
shorten immobility time in the forced swimming test, indicat-
ing cynomorium total flavone can increase the curiosity of per-
imenopausal rats on fresh environment, increase the reaction
intensity on rewards, and decrease the degree of desperation
on adverse environment, so as to improve depressive symptom.
First, cynomorium total flavone can significantly increase the
initially reduced level of E2 (Pachman et al., 2010) and T in
the serum of perimenopausal rats with depression, indicating
cynomorium total flavone can adjust the disorders of hormone
levels and hypothalamic-pituitary-gonadal function of peri-
menopausal rats with depression (Wiacek et al., 2011). Sec-
ondly, cynomorium total flavone can significantly increase
the contents of 5-HT and DA in the brain homogenate of per-
imenopausal rats with depression, indicating cynomorium
total flavone is used in the prospect of treating perimenopausal
depression, wherein the mechanism is to realize the adjustment
of monoamine neurotransmitters through impacting
hypothalamic-pituitary-gonadal axis. Thirdly, cynomorium
total flavone can significantly increase the positive expressions
of ER (Kammerer et al., 2013) and AR in hypothalamus,
hypophysis, ovary, and uterus, indicating that cynomorium
total flavone can basically enhance the biological effect of
estrogen and androgen, and its function of increasing the pos-
itive expressions of ER and AR is probably related to the
increased contents of estrogen and androgen.
Through experiment results, it can be seen that the adjust-
ment function of cynomorium total flavone to perimenopausal
syndrome is realized by mainly increasing the level of E2, how-
ever the further molecular mechanism still remains to be
explored. The increased level of E2 adjusts the disorder of
hypothalamic-pituitary-gonad axis, making related biomedical
indexes such as 5-HT, DA, ER, AR, and ERmRNA tend to be
normal, so as to relieve the symptoms of perimenopausal syn-
drome and perimenopausal syndrome with depression.
Currently, regarding the duplication of perimenopausal
depression model, mostly refer to the duplication of single per-
imenopause model or depression model; however this paper
successfully duplicated the model of perimenopause with
depression, which is the first difference from that in previous
researches. In addition, in the situation where few researches
are conducted on the effect of cynomorium total flavone on
perimenopausal depression, this experiment further explores
pharmacological action of cynomorium total flavone, which
is the second difference from that of previous researches.
148 M. Miao et al.Moreover, as a common Chinese medicine for male, cynomo-
rium was used to treat female menopause diseases, which is a
novel research approach of ‘‘reverse balance of cure and tone”,
providing a new treatment approach for body function imbal-
ance diseases such as climacteric syndrome, uterine hypoplasia,
hyperplasia of mammary glands, and male reproductive
function diseases, which is the third difference from that in pre-
vious researches. Finally, with characteristics of high effective-
ness, lower cost and convenience, cynomorium total flavone
enjoys a wide planting area in China, therefore developing
new drugs or health care products based on cynomorium total
flavone can enhance the full use of Chinese material medicine
resource. The experimental results of this paper show that
cynomorium total flavone is of sound therapeutic effect to per-
imenopausal depression of rats, providing a scientific basis for
regarding cynomorium total flavone as a preventive drug for
perimenopausal depression and providing a new approach
for developing new drugs based on cynomorium for peri-
menopausal depression.
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